Apollomics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG0411D1079
USD
16.27
1.53 (10.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

6.75 k

Shareholding (Dec 2024)

FII

0.07%

Held by 3 FIIs

DII

90.97%

Held by 1 DIIs

Promoter

7.78%

How big is Apollomics, Inc.?

22-Jun-2025

As of Jun 18, Apollomics, Inc. has a market capitalization of 7.01 million and reported net sales of 0.00 million with a net profit of -0.83 million over the last four quarters. The balance sheet shows shareholder's funds of 4.86 million and total assets of 13.10 million.

As of Jun 18, Apollomics, Inc. has a market capitalization of 7.01 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -0.83 million during the same period.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of 4.86 million and total assets amounting to 13.10 million.

Read More

What does Apollomics, Inc. do?

22-Jun-2025

Apollomics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting no net profit and a market cap of $7.01 million. Key financial metrics indicate it is loss-making with a negative return on equity and no dividend yield.

Overview: <BR>Apollomics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: 0 Million (Quarterly Results - Sep 2022) <BR>Market cap: USD 7.01 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.96 <BR>Return on Equity: -848.64% <BR>Price to Book: 1.44<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Apollomics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Apollomics, Inc. shows a mildly bearish trend overall, with mixed technical indicators, including a mildly bullish MACD and bearish RSI, while significantly outperforming the S&P 500 in the past week and month.

As of 29 August 2025, the technical trend for Apollomics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bearish on the weekly and shows no signal on the monthly. The moving averages indicate a mildly bearish trend on the daily. Additionally, the Bollinger Bands are bullish weekly but mildly bearish monthly, and the KST is bullish weekly but bearish monthly. Despite the mildly bearish outlook, the stock has significantly outperformed the S&P 500 over the past week (190.79% vs. 1.05%) and month (217.46% vs. 2.33%).

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.96

stock-summary
Return on Equity

-848.64%

stock-summary
Price to Book

1.23

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2022)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
215.31%
0%
215.31%
6 Months
150.31%
0%
150.31%
1 Year
92.32%
0%
92.32%
2 Years
-80.63%
0%
-80.63%
3 Years
59.66%
0%
59.66%
4 Years
64.34%
0%
64.34%
5 Years
0%
0%
0.0%

Apollomics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-21.95%
EBIT to Interest (avg)
-11.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.96
Sales to Capital Employed (avg)
0
Tax Ratio
0.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.45%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.49
EV to EBIT
0.05
EV to EBITDA
0.05
EV to Capital Employed
0.48
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
906.70%
ROE (Latest)
-848.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (1.18%)

Foreign Institutions

Held by 3 Foreign Institutions (0.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Apollomics, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.77% vs 28.32% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.00",
          "val2": "-54.10",
          "chgp": "22.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.60",
          "val2": "-74.00",
          "chgp": "82.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-53.90",
          "val2": "-172.60",
          "chgp": "68.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-42.00
-54.10
22.37%
Interest
0.20
0.20
Exceptional Items
-12.60
-74.00
82.97%
Consolidate Net Profit
-53.90
-172.60
68.77%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.77% vs 28.32% in Dec 2023

stock-summaryCompany CV
About Apollomics, Inc. stock-summary
stock-summary
Apollomics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available